A Randomized Parallel-group, Placebo-controlled, Double-blind, Multi-centre Dose Finding Phase II Trial Exploring the Pharmacodynamic Effects, Safety and Tolerability, and Pharmacokinetics of Four Dose Regimens of the Oral sGC Stimulator BAY1021189 Over 12 Weeks in Patients With Worsening Heart Failure and Preserved Ejection Fraction (HFpEF)
Latest Information Update: 09 Dec 2021
At a glance
- Drugs Vericiguat (Primary)
- Indications Chronic heart failure
- Focus Pharmacodynamics
- Acronyms SOCRATES-PRESERVED
- Sponsors Bayer; Bayer HealthCare
- 22 Mar 2017 Primary endpoint (Change of log-transformed N-terminal pro-brain natriuretic peptide (NT-proBNP)) has not been met, according to the results published in the European Heart Journal
- 22 Mar 2017 Primary endpoint (Change of left atrial volume) has not been met, according to the results published in the European Heart Journal
- 22 Mar 2017 Results published in the European Heart Journal